Stay updated with breaking news from Dose Exploration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual MeetingOn track for completion of enrollment... | May 10, 2023
With concerning survival, toxicity data, ODAC calls for randomized trials to support approvals